Fig. 1.
Progression-free survival among 138 patients with advanced pancreatic neuroendocrine tumors treated with temozolomide (TEM) or TEM-capecitabine (TEM-CAP). a Raw analysis. b Analysis of patients matched for their propensity score. c Analysis using the inverse probability treatment weighting method.